Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03448666
Title ECT-Pembrolizumab in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral Metastases
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors European Institute of Oncology
Indications
Therapies
Age Groups: adult | senior
Covered Countries ITA

Facility Status City State Zip Country Details
IEO Istituto Europeo di Oncologia Milan 20141 Italy Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field